within Pharmacolibrary.Drugs.ATC.L;

model L01BC08
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.004966666666666666,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.045700000000000005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0495,
    k12             = 481,
    k21             = 481
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01BC08</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Decitabine is a DNA methyltransferase inhibitor used primarily in the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). It is a cytidine analog that is incorporated into DNA, resulting in hypomethylation and activation of silenced genes. Decitabine is approved for medical use in various countries, including the US and EU, for hematological malignancies.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) following intravenous administration.</p><h4>References</h4><ol><li><p>Garcia-Manero, G, et al., &amp; Savona, MR (2024). Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. <i>The Lancet. Haematology</i> 11(1) e15–e26. DOI:<a href=\"https://doi.org/10.1016/S2352-3026(23)00338-1\">10.1016/S2352-3026(23)00338-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38135371/\">https://pubmed.ncbi.nlm.nih.gov/38135371</a></p></li><li><p>Geissler, K, et al., &amp; Lübbert, M (2024). Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study. <i>British journal of haematology</i> 205(5) 1734–1745. DOI:<a href=\"https://doi.org/10.1111/bjh.19741\">10.1111/bjh.19741</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39313917/\">https://pubmed.ncbi.nlm.nih.gov/39313917</a></p></li><li><p>Bouligny, IM, &amp; DiNardo, CD (2024). Oral decitabine-cedazuridine in acute myeloid leukaemia. <i>British journal of haematology</i> 205(5) 1674–1676. DOI:<a href=\"https://doi.org/10.1111/bjh.19769\">10.1111/bjh.19769</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39313925/\">https://pubmed.ncbi.nlm.nih.gov/39313925</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01BC08;
